Skip to main content
Premium Trial:

Request an Annual Quote

Leica Bio, ACD Ink Co-marketing Agreement

NEW YORK (GenomeWeb) – Leica Biosystems and Advanced Cell Diagnostics today announced a co-marketing agreement covering their respective technologies to provide an integrated and fully automated in situ hybridization solution.

The firms will co-market ACD's RNAscope LS ISH assays with Leica's BOND RX research staining platform. The assays provide researchers a method for robust single RNA molecule detection for formalin-fixed, paraffin-embedded tissue. Since their introduction three years ago, biotech firms have used the RNAscope assays for drug discovery, translational research, and the development of clinical and companion diagnostic tests, the companies said.

Financial and other terms of the deal were not disclosed.

Earlier this week, ACD said that it received ISO 13485-2003 certification for its diagnostic kits, enabling it to launch the RNAscope product lines in Europe.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.